Roivant Telavant Acquisition by Roche 2023

Loading viewer...

investor_presentation

Format: PDF investor_presentation

Roivant announced the sale of its Telavant subsidiary to Roche for $7.1 billion upfront plus $150 million in milestone payments. The transaction includes development and commercial rights to RVT-3101 in the US and Japan, with Pfizer retaining rights outside these regions. Expected to close in Q4 2023 or Q1 2024.

Browse all investor_presentations →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Roivant Sciences

View all →

Roivant Sciences November 2023 Overview Presentation

investor_presentation

93 Pages

Roivant Sciences Overview April 2024

investor_presentation

Similar investor_presentations from other companies

Browse all →

Independence Contract Drilling ICD Investor Presentation March 2022

investor_presentation

34 Pages

Independence Contract Drilling

Valmet Roadshow 2018: Process Technology Automation Services

investor_presentation